Frequent Emergence of Resistance Mutations Following Complex Intra-Host Genomic Dynamics in SARS-CoV-2 Patients Receiving Sotrovimab

Authors:

Abstract
The emergence of the Omicron variant of SARS-CoV-2 represented a challenge to the treatment of COVID-19 using monoclonal antibodies. Only Sotrovimab maintained partial activity, allowing it to be used in high-risk patients infected with the Omicron variant.
Keywords
All Related Versions
Funding Information
  • MEC | Instituto de Salud Carlos III (PI21/01823)

This publication has 15 references indexed in Scilit: